Longeveron Inc. (NASDAQ:LGVN) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET
Company Representatives
Dr. Chris Min - Interim Chief Executive Officer, Chief Medical Officer
Dr. Joshua Hare - Co-Founder, Chief Science Officer, Chairman
James Clavijo - Chief Financial Officer
Elsie Yau - Stern Investor Relations
Conference Call Participants
Michael Okunewitch - Maxim Group
Operator
Good morning or good afternoon, and welcome to the Longeveron Inc., 2022 Third Quarter Earnings Call. My name is Ajay and I will be your operator today. [Operator Instructions]
I would now like to turn the call over to Elsie Yau from Stern Investor Relations. Elsie, you may proceed.
Elsie Yau
Thank you, operator. Good morning, everyone, and welcome to Longeveron, third quarter 2022 call. Today we will provide a business update and discuss financial results for the third quarter of 2022. Earlier this morning we issued a press release with these results, which can be found under the Investor section of our website at www.longeveron.com.
I'm joined on the call today by the following members of Longeveron's Management team; Dr. Chris Min, Interim Chief Executive Officer and Chief Medical Officer; Dr. Joshua M. Hare, Co-Founder, Chief Science Officer and Chairman; and James Clavijo, Chief Financial Officer.
Dr. Min will begin with a brief corporate overview, followed by a review of update from Longeveron's clinical program in Alzheimer's disease, Hypoplastic Left Heart Syndrome or HLHS and Aging Frailty. Then Mr. Clavijo will review our third quarter financials. Last, we will then open the call for Q&A.
As a reminder, during this call, we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussion in our filings with the SEC, including our Annual Report on Form 10-K, and cautionary statements made on this call. We assume no obligation to update any of these forward-looking statements or information.
Now, I'd like to turn the call over to Dr. Chris Min, Interim Chief Executive Officer and Chief Medical Officer of Longeveron. Chris.
Dr. Chris Min
Thank you, Elsie. Good morning, everyone, and welcome to Longeveron third quarter 2022 business update and financial results call. Longeveron is a clinical stage biotechnology company developing regenerative medicines for unmet medical needs. At Longeveron, our mission is to develop safe and effective cell-based therapies for some of the most challenging disorders associated with the aging process and other medical disorders.